Enzymatica Q1: Continued growth in own markets, but a lack of partner orders - Redeye

Redeye provides an update following Enzymatica’s Q1 report. The quarter’s sales did not meet our expectations, which resulted from low partner orders. We argue the company has an important time ahead and view a rise in partner sales as a trigger for the share. Moreover, we make changes to our sales estimates, rendering an updated fair value range.

Länk till analysen i sin helhet: https://www.redeye.se/research/999169/enzymatica-q1-continued-growth-in-own-markets-but-a-lack-of-partner-orders?utm_source=finwire&utm_medium=RSS